Browse the evidence

Inhibition of sphingolipid synthesis (specifically via SPT inhibition by myriocin or CerS inhibition by fumonisin B1) extends lifespan in model organisms like yeast and C. elegans, suggesting that reducing ceramide production can delay aging.

Research in simple organisms shows that reducing the production of certain lipids (sphingolipids) can extend lifespan. This suggests that metabolic pathways involving lipid synthesis are key regulators of aging. For humans, this points to the importance of metabolic health and lipid balance, though direct application of inhibitors like myriocin is not currently a standard human intervention.

Inhibition of cyclooxygenase (COX) activity prevents the induction of UCP1 in white adipose tissue (WAT), thereby reducing diet-induced thermogenesis and promoting increased adiposity.

This research suggests that chronic use of COX inhibitors (like indomethacin, and potentially NSAIDs like ibuprofen) might interfere with your body's ability to burn fat through 'browning' of white fat, especially if you are not exercising in cold environments. For most people, occasional use is fine, but if you are trying to maximize metabolic efficiency, be aware that these drugs might blunt a specific fat-burning pathway.

The novel rapamycin analog DL001 selectively inhibits mTORC1 in vivo without disrupting glucose or lipid homeostasis, unlike conventional rapamycin which causes metabolic side effects via mTORC2 inhibition.

This research identifies a specific compound (DL001) that inhibits the mTORC1 pathway without causing the metabolic side effects (like high blood sugar and bad cholesterol) seen with standard rapamycin. While promising for treating age-related diseases and tuberous sclerosis in future human trials, it is not currently available for general use. The key takeaway is that selective mTORC1 inhibition may be a viable strategy to avoid metabolic disruption.

DL001 effectively suppresses hyperactive mTORC1 signaling in cells lacking a functional TSC (Tuberous Sclerosis Complex), restoring normal gene expression.

DL001 is shown to be as effective as rapamycin in suppressing the overactive mTORC1 signaling found in Tuberous Sclerosis Complex (TSC) cells. This suggests DL001 could be a safer alternative for treating TSC, as it may avoid the metabolic side effects associated with current rapalog treatments, although this is currently limited to cell culture models.

Low-dose lithium supplementation (1-25 mM in Drosophila) extends median and maximum lifespan and healthspan independently of sex and genetic background.

This study identifies lithium as a pro-longevity agent in fruit flies, extending lifespan by 16-18% at low doses (1-25 mM) without reducing food intake or fertility. The mechanism involves inhibiting GSK-3 to activate NRF-2, enhancing stress resistance. While promising, human translation requires caution due to the narrow therapeutic window and potential toxicity at higher doses. Future human trials may explore low-dose, intermittent, or late-life administration to maximize benefits while minimizing renal risks.

Activation of cholecystokinin-expressing neurons in the nucleus of the solitary tract (CCKNTS) projecting to the paraventricular hypothalamus (PVH) suppresses appetite and reduces body weight in mice.

This research highlights that appetite is regulated by a specific neural circuit in the brainstem that responds to nutrients. While this specific optogenetic intervention is not applicable to humans, it suggests that the feeling of satiety is a robust biological signal mediated by cholecystokinin. For practical purposes, this supports the importance of consuming nutrient-dense foods that trigger natural satiety signals, rather than relying on caloric volume alone.

Substituting pro-aging carbon sources (glucose and ethanol) with glycerol in yeast mimics the life-span extension effects of calorie restriction by activating stress resistance pathways without triggering pro-aging signaling.

While this study is in yeast, it suggests that the type of fuel your body uses matters for longevity. Replacing high-glycemic fuels (like glucose/ethanol equivalents) with more stable metabolic byproducts (like glycerol in this context) can mimic the benefits of calorie restriction. For humans, this implies that managing insulin and nutrient-sensing pathways (Tor/Sch9 homologs) through diet composition, not just caloric restriction, is crucial for longevity.

Adiponectin replacement therapy reverses insulin resistance and reduces atherosclerosis in animal models of obesity and diabetes.

This paper highlights that low levels of the hormone adiponectin are linked to insulin resistance and atherosclerosis in obese individuals. While replacing adiponectin has shown promising results in animal studies, human treatments are not yet available. For now, maintaining a healthy weight and engaging in regular physical activity are the best ways to support your body's natural adiponectin levels.

Impaired kisspeptin signaling in adult male mice does not result in obesity or glucose intolerance, demonstrating a strong sexual dimorphism in metabolic regulation.

Metabolic consequences of kisspeptin signaling impairment appear to be specific to females in this model. Males with the same genetic impairment maintain normal body weight and glucose regulation.

In long-standing extensive alopecia areata (EAA), T-cells in the scalp exhibit a state of partial tolerance characterized by reduced production of IL-2 and IFN-gamma, resulting in a paucity of inflammatory change and preventing follicle destruction.

For those with long-standing hair loss, the issue may not be active inflammation to be fought, but a specific immune tolerance where T-cells stop producing key growth signals (IL-2) and inflammatory markers (IFN-gamma). This suggests treatments might need to address this specific 'tolerance' state rather than just suppressing general inflammation.

Plasma estradiol (E2) levels are not associated with all-cause or ischemic heart disease (IHD) mortality in older men.

For older men, estradiol levels do not appear to be a predictor of survival or heart disease death. This suggests that strategies to optimize longevity in this age group should focus on testosterone and DHT rather than estradiol manipulation.

Long-term pharmacological inhibition of mTOR using rapamycin extends the lifespan of mice, with a more pronounced effect in females than males, though it carries significant metabolic and immunological side effects.

While rapamycin extends lifespan in mice, its use in healthy humans is currently limited by side effects like immune suppression and insulin resistance. Current research explores intermittent dosing or specific mTORC1-selective inhibitors to mitigate these risks. For now, lifestyle interventions like calorie restriction or low-protein diets may offer safer, sustainable ways to modulate the mTOR pathway without the severe pharmacological risks.

Cideb deficiency improves insulin sensitivity in the liver by increasing tyrosine phosphorylation of IRS-1 and phosphorylation of AKT, independent of changes in adiposity.

This study suggests that targeting liver-specific pathways like Cideb can improve insulin sensitivity without requiring immediate weight loss. This highlights the importance of metabolic health markers (like insulin sensitivity) beyond just body weight. Future therapies might target these specific liver mechanisms to treat type 2 diabetes and metabolic syndrome.

Brain-specific overexpression of SIRT1 extends lifespan and delays aging phenotypes in mice, primarily through hypothalamic regulation of metabolic homeostasis and circadian rhythms.

Current research suggests that longevity benefits from SIRT1 are specific to brain regions (hypothalamus) and cannot be assumed from global activation. While activators like SRT1720 show promise in mice, human application requires targeted mechanisms, not just general supplementation.

Central nervous system (CNS) activation of GLP-1 receptors directly reduces peripheral lipid deposition in white adipose tissue (WAT) by modulating sympathetic nervous system (SNS) outflow, independent of changes in food intake.

Central GLP-1 signaling can directly tell fat cells to store less fat, independent of how much you eat. This happens through the sympathetic nervous system. However, this direct fat-reducing signal is lost in obesity, meaning this mechanism may not work for people who are already obese.

The ability of CNS GLP-1 to reduce fat storage is blunted in diet-induced obesity (DIO) due to a loss of sympathetic nervous system signaling to adipocytes.

In obese individuals, the brain's direct signal to burn fat via GLP-1 is blocked. This suggests that treatments relying solely on this pathway may be less effective for weight loss in obese people unless the resistance is overcome.

Dehydroepiandrosterone (DHEA) levels are not associated with the risk of incident type 2 diabetes in postmenopausal women.

Unlike testosterone, estradiol, and SHBG, DHEA levels do not appear to predict diabetes risk in postmenopausal women. You do not need to monitor or target DHEA for diabetes prevention.

Specific miRNAs (let-7e-5p, miR-210-3p) packaged in liver-derived EVs directly target Pgc1α in adipocytes to inhibit mitochondrial biogenesis and promote lipid accumulation.

This explains how liver signals suppress fat-burning (mitochondrial biogenesis) in fat cells. It suggests that high liver-to-fat signaling may contribute to obesity by actively suppressing fat oxidation.

Adverse intrauterine environments, including maternal malnutrition, high-fat diets, and obesity, program the offspring's metabolism to increase the risk of adult metabolic syndrome, type 2 diabetes, and cardiovascular disease through structural, epigenetic, and hormonal changes.

Your metabolic health is heavily influenced by your mother's health during pregnancy, not just your own diet today. While you cannot change your prenatal history, understanding this link highlights the importance of prenatal care and suggests that maintaining a healthy lifestyle post-birth is critical to mitigating programmed risks, even if it doesn't fully reverse them.

Maternal high-fat diet and obesity during pregnancy program offspring leptin resistance and altered adiponectin levels, leading to increased adiposity and insulin resistance in the offspring regardless of postnatal diet.

If your mother had a high-fat diet or obesity during your pregnancy, you may have inherent leptin resistance, making weight management harder. This is not your fault, but it means you may need to be more vigilant with your diet and exercise to overcome this biological predisposition.

Prophylactic administration of uPAR-targeting CAR T cells in young mice prevents the development of age-related metabolic dysfunction and maintains exercise capacity into old age.

Treating young organisms with senolytic CAR T cells can prevent metabolic decline and maintain physical fitness into old age. This suggests that early intervention might be more effective than late-stage treatment.

Prenatal exposure to tributyltin (TBT) permanently reprograms mesenchymal stem cells (MSCs) to favor adipogenesis over osteogenesis, leading to increased body fat and insulin resistance in offspring.

Avoid sources of tributyltin (TBT), such as contaminated seafood from areas with heavy marine shipping or old boat paint, and ensure home plumbing does not involve leaching organotins from PVC pipes, particularly for pregnant women.

Rapamycin extends maximal lifespan in mice primarily by suppressing lethal neoplastic disease (cancer) rather than by slowing the fundamental rate of biological aging.

While rapamycin extends mouse lifespan, current evidence suggests this is due to cancer suppression, not a general slowing of aging. Symptomatic benefits (like improved cognition) are observed but appear to be independent of age. Human translation requires caution as cancer risk profiles differ, and symptomatic benefits may not imply slowed biological aging.

Genetic heterozygosity for the ER chaperone Grp78 (BiP) promotes an adaptive unfolded protein response (UPR) in white adipose tissue, which attenuates diet-induced obesity, insulin resistance, and hyperglycemia.

This research identifies a specific genetic mechanism (Grp78 heterozygosity) that protects against diet-induced obesity and insulin resistance by enhancing the cell's ability to handle stress (UPR). While this specific genetic modification is not a lifestyle intervention, it suggests that strategies which mildly activate adaptive stress responses (hormesis) in fat cells may improve metabolic health. Current research points to ER stress modulation as a potential therapeutic target for obesity and type 2 diabetes.